6 Refined classification reflects the genotypic and phenotypic differences among the various types of these tumors and may lead to more appropriate clinical management and development of more effective forms of therapy. N engl J Med 374;2 January 14,

34 The overall response rate for non-ccrcc with targeted agents was 10.5%. In studies directly comparing non-ccrcc and ccrcc, there were significantly lower response rates for non-ccrcc For non-ccrcc treated with targeted agents. median PFS and OS were 7.4 and 13.4 mo, respectively; for patients with ccrcc, these were 10.5 mo and 15.7 mo

The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma Robert A. Figlin MD., FACP Acting Director City of Hope Comprehensive Cancer Center Cytoreductive Surgery

The trial and tribulations of predictive biomarkers in metastatic RCC. Professor Thomas Powles Renal cancer lead for London Cancer Barts Cancer Institute and Royal Free Hospital UCL and QMUL. Proportion

Renal tumours WHO 4 MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours G. KOVACS A CLASSIFICATION BASED ON UNDERSTANDING THE GENETIC

The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair

Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms Wolfram Samlowski, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

Challenges for Patients on Long Term Systemic Therapy Prof. Cezary Szczylik, MD PhD Department of Oncology Military Institute of Medicine Warsaw Poland What are the challenges? How long is long-term? Which

The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma Steven Shen, M.D.,Ph.D. Staff Pathologist and Assistant Member The Methodsit Hospital and Research Institute

Design of Randomized Phase II Clinical Trials with a Potential Predictive Biomarker Ed Korn Biometric Research Branch National Cancer Institute Phase II trials are designed to decide whether to take an

What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

Advanced Renal Cell Carcinoma Individualizing Treatment Selection in the Era of Targeted Therapy Renal Cell Carcinoma In the United States in 28: 54,9 estimated new cases of RCC, estimated deaths Median

Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information